EXHIBIT 12.1

ARIAD Pharmaceuticals, Inc.
Computation of Deficiency of Earnings to Fixed Charges

																Nine Months
																Ended
	Year Ended December 31,															September 30,
	2004			2005			2006			2007			2008			2009
	($ in thousands)
Earnings (loss):
Pretax income from continuing operations	$	(35,573	)	$	(55,482	)	$	(61,928	)	$	(58,522	)	$	(71,052	)	$	(62,000	)
Fixed charges (from below)		395			587			606			481			705			339
Amortization of capitalized interest		0			14			14			14			0			0
Interest capitalized		0			(42	)		0			0			0			0
Total earnings (loss)	$	(35,178	)	$	(54,923	)	$	(61,308	)	$	(58,027	)	$	(70,347	)	$	(61,661	)
Fixed charges:
Interest expensed	$	272		$	422		$	483		$	337		$	550		$	225
Interest capitalized		0			42			0			0			0			0
Interest portion of rent expense		123			123			123			144			155			114
	$	395		$	587		$	606		$	481		$	705		$	339
Coverage deficiency	$	35,573		$	55,510		$	61,914		$	58,508		$	71,052		$	62,000